# Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

> **NCT03377101** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Estrogen Receptor Positive
- HER2/Neu Negative
- Progesterone Receptor Positive
- Stage IV Breast Cancer AJCC v6 and v7

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Fulvestrant
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03377101
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-08-07
- **Primary completion:** 2018-08-07
- **Final completion:** 2018-08-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** change in study design.
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377101, "Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03377101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*